Video

Dr. Sandler on Radiation Therapy for Prostate Cancer

Howard M. Sandler, MD, discusses the RTOG 94-06 study, which analyzed three dimensional conformal radiation therapy and intensity-modulated radiation therapy (IMRT) for patients with prostate cancer.

Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses the RTOG 94-06 study, which analyzed three dimensional conformal radiation therapy and intensity-modulated radiation therapy (IMRT) for patients with prostate cancer.

In this study, patients were randomized to 70.2 Gy or 79.2 Gy. A recent secondary analysis looked at the high dose arm (79.2 Gy), as some patients were treated with 3-D conformal therapy and others were treated with IMRT.

IMRT is a more focused form of radiation therapy, Sandler says, so it was no surprise that the IMRT cohort of patients saw a slight decrease in rectal toxicity.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic